Shares of Intra-Cellular Therapies Inc (NASDAQ:ITCI) have been given an average recommendation of “Buy” by the fourteen research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and eleven have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $29.56.
Several equities analysts recently commented on the stock. BidaskClub raised shares of Intra-Cellular Therapies from a “strong sell” rating to a “sell” rating in a research report on Friday, January 5th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $28.00 price target on shares of Intra-Cellular Therapies in a research report on Thursday, March 1st. Canaccord Genuity set a $31.00 price target on shares of Intra-Cellular Therapies and gave the stock a “buy” rating in a research report on Tuesday, March 13th. ValuEngine lowered shares of Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research report on Tuesday, December 5th. Finally, Cowen reaffirmed a “buy” rating and set a $28.00 price target on shares of Intra-Cellular Therapies in a research report on Friday, March 2nd.
Intra-Cellular Therapies (NASDAQ ITCI) opened at $23.40 on Friday. The firm has a market cap of $1,311.24, a P/E ratio of -11.04 and a beta of 0.66. Intra-Cellular Therapies has a 52-week low of $7.85 and a 52-week high of $25.82.
Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.06). The firm had revenue of $5.06 million during the quarter, compared to analyst estimates of $0.05 million. Intra-Cellular Therapies had a negative net margin of 39,745.53% and a negative return on equity of 26.67%. The business’s quarterly revenue was down 94.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.64) EPS. research analysts anticipate that Intra-Cellular Therapies will post -3.33 earnings per share for the current fiscal year.
In other Intra-Cellular Therapies news, VP Lawrence J. Hineline sold 49,700 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $20.02, for a total transaction of $994,994.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Lawrence J. Hineline sold 3,192 shares of the business’s stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $15.67, for a total transaction of $50,018.64. Following the sale, the chief financial officer now owns 68,686 shares of the company’s stock, valued at $1,076,309.62. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 98,210 shares of company stock valued at $1,846,548. 21.00% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. MetLife Investment Advisors LLC purchased a new stake in Intra-Cellular Therapies during the fourth quarter worth approximately $246,000. Millennium Management LLC grew its stake in Intra-Cellular Therapies by 18.0% during the fourth quarter. Millennium Management LLC now owns 1,454,944 shares of the biopharmaceutical company’s stock worth $21,068,000 after buying an additional 221,980 shares during the period. TIAA CREF Investment Management LLC grew its stake in Intra-Cellular Therapies by 61.5% during the fourth quarter. TIAA CREF Investment Management LLC now owns 174,620 shares of the biopharmaceutical company’s stock worth $2,528,000 after buying an additional 66,464 shares during the period. Teachers Advisors LLC grew its stake in Intra-Cellular Therapies by 25.5% during the fourth quarter. Teachers Advisors LLC now owns 78,406 shares of the biopharmaceutical company’s stock worth $1,135,000 after buying an additional 15,912 shares during the period. Finally, Raymond James & Associates purchased a new stake in Intra-Cellular Therapies during the fourth quarter worth approximately $237,000. Institutional investors own 70.47% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://ledgergazette.com/2018/03/20/intra-cellular-therapies-inc-itci-receives-29-56-average-target-price-from-analysts.html.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.